FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033593985> ?p ?o ?g. }

• W3033593985 abstract "Abstract Background and Aims Hyperuricemia is associated with rapid deterioration of renal function in patients with chronic kidney disease (CKD). The two most common urate-lowering drugs available in the market are allopurinol and febuxostat. Randomized controlled trials (RTCs) have shown that the individual drugs have potential to slow down progression of renal function in patients with chronic kidney disease (CKD) and hyperuricemia. However, it is unclear which drug is more effective because of insufficient direct comparison between the two. Hence our study aims to perform a meta-analysis of RCTs to assess the renoprotective and urate-lowering effects between the two drugs in patients with CKD and hyperuricemia. Method A comprehensive literature search of randomized controlled trials using PubMed was performed with the following search terms: febuxostat, allopurinol, chronic kidney disease, renoprotection. Four prospective RCTs were selected and analyzed using Cochrane Revman v5.3. Outcomes assessed were change in serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria and serum uric acid levels from baseline to 3 months post-initiation of therapy. Results Four relevant trials comprising of 486 patients were selected - 247 patients treated with febuxostat and 239 patients with allopurinol. No significant differences were found in the changes in serum creatinine (mean difference -0.04; CI -0.15, 0.07; P = 0.51) and eGFR (mean difference 1.57; CI -0.83, 3.97; P = 0.20) from baseline to 3 months between the febuxostat and allopurinol group. Decrease in proteinuria was significantly observed more in the febuxostat group (mean difference -50.13; CI -90.54; -9.71, P = 0.02). Similarly, serum uric acid levels were significantly more reduced in the febuxostat group (mean difference -1.11; CI -1.53, -0.68, P &lt; 0.00001). Conclusion Our study showed that febuxostat is non-inferior in terms of delaying renal function decline (as measured by eGFR) but it offers a better anti-proteinuric as well as a urate-lowering effect. However, more studies are needed to assess the efficacy of febuxostat across the spectrum of chronic kidney disease, including those requiring hemodialysis." @default.
• W3033593985 created "2020-06-12" @default.
• W3033593985 creator A5008299793 @default.
• W3033593985 creator A5027737518 @default.
• W3033593985 creator A5073946507 @default.
• W3033593985 date "2020-06-01" @default.
• W3033593985 modified "2023-09-27" @default.
• W3033593985 title "SO012RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND CHRONIC KIDNEY DISEASES: A META-ANALYSIS" @default.
• W3033593985 doi "https://doi.org/10.1093/ndt/gfaa139.so012" @default.
• W3033593985 hasPublicationYear "2020" @default.
• W3033593985 type Work @default.
• W3033593985 sameAs 3033593985 @default.
• W3033593985 citedByCount "0" @default.
• W3033593985 crossrefType "journal-article" @default.
• W3033593985 hasAuthorship W3033593985A5008299793 @default.
• W3033593985 hasAuthorship W3033593985A5027737518 @default.
• W3033593985 hasAuthorship W3033593985A5073946507 @default.
• W3033593985 hasBestOaLocation W30335939851 @default.
• W3033593985 hasConcept C126322002 @default.
• W3033593985 hasConcept C126894567 @default.
• W3033593985 hasConcept C159641895 @default.
• W3033593985 hasConcept C168563851 @default.
• W3033593985 hasConcept C2778653478 @default.
• W3033593985 hasConcept C2779561371 @default.
• W3033593985 hasConcept C2779721657 @default.
• W3033593985 hasConcept C2779881121 @default.
• W3033593985 hasConcept C2780091579 @default.
• W3033593985 hasConcept C2780261098 @default.
• W3033593985 hasConcept C2780306776 @default.
• W3033593985 hasConcept C2780402116 @default.
• W3033593985 hasConcept C2780932893 @default.
• W3033593985 hasConcept C71924100 @default.
• W3033593985 hasConceptScore W3033593985C126322002 @default.
• W3033593985 hasConceptScore W3033593985C126894567 @default.
• W3033593985 hasConceptScore W3033593985C159641895 @default.
• W3033593985 hasConceptScore W3033593985C168563851 @default.
• W3033593985 hasConceptScore W3033593985C2778653478 @default.
• W3033593985 hasConceptScore W3033593985C2779561371 @default.
• W3033593985 hasConceptScore W3033593985C2779721657 @default.
• W3033593985 hasConceptScore W3033593985C2779881121 @default.
• W3033593985 hasConceptScore W3033593985C2780091579 @default.
• W3033593985 hasConceptScore W3033593985C2780261098 @default.
• W3033593985 hasConceptScore W3033593985C2780306776 @default.
• W3033593985 hasConceptScore W3033593985C2780402116 @default.
• W3033593985 hasConceptScore W3033593985C2780932893 @default.
• W3033593985 hasConceptScore W3033593985C71924100 @default.
• W3033593985 hasLocation W30335939851 @default.
• W3033593985 hasOpenAccess W3033593985 @default.
• W3033593985 hasPrimaryLocation W30335939851 @default.
• W3033593985 hasRelatedWork W10780070 @default.
• W3033593985 hasRelatedWork W12387188 @default.
• W3033593985 hasRelatedWork W13122835 @default.
• W3033593985 hasRelatedWork W15763632 @default.
• W3033593985 hasRelatedWork W19167177 @default.
• W3033593985 hasRelatedWork W3232781 @default.
• W3033593985 hasRelatedWork W6046820 @default.
• W3033593985 hasRelatedWork W7893890 @default.
• W3033593985 hasRelatedWork W9393729 @default.
• W3033593985 hasRelatedWork W4488339 @default.
• W3033593985 isParatext "false" @default.
• W3033593985 isRetracted "false" @default.
• W3033593985 magId "3033593985" @default.
• W3033593985 workType "article" @default.